semaglutide for the treatment of obesity as a GLP-1 Agonist: A Breakthrough in Current Strategies in Managing Obesity

What these medications are not is a one-time cure that permanently rewires human biology after a few months of use

Full analysis #GLP1 #EmployeeBenefits #HealthcareCosts #WorkforceHealth #Aon Farheen Dam Doug Melton Lisa Stevens Laura Rissover Liz Parr Lindsay Dower, MHA Kembre Roberts, PhD Workforce-Focused Analysis on GLP-1s: Phase Two Findings aon.com To view or add a comment, sign in Novo Nordisks FDA-approved Wegovy pill, as highlighted by Ferrin Williams, PharmD MBA, marks a major shift in obesity careintroducing an oral GLP-1 option that could expand access, improve adherence, and reshape how clinicians manage chronic weight conditions

By stimulating growth hormone production, the bodys metabolism improves, helping to break down fat more efficiently

This means that rebates from insurance coverage are not being collected by the insurance company

Microglial glucagon-like peptide-1 receptor (GLP-1R) activation can alleviate pain